SI2114405T1 - Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona - Google Patents

Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona

Info

Publication number
SI2114405T1
SI2114405T1 SI200731644T SI200731644T SI2114405T1 SI 2114405 T1 SI2114405 T1 SI 2114405T1 SI 200731644 T SI200731644 T SI 200731644T SI 200731644 T SI200731644 T SI 200731644T SI 2114405 T1 SI2114405 T1 SI 2114405T1
Authority
SI
Slovenia
Prior art keywords
methanone
piperazin
methanesulfonyl
trifluoro
pyridin
Prior art date
Application number
SI200731644T
Other languages
English (en)
Slovenian (sl)
Inventor
Andre Bubendorf
Annette Deynet-Vucenovic
Ralph Diodone
Olaf Grassmann
Kai Lindenstruth
Emmanuel Pinard
Franziska E. Rohrer
Urs Schwitter
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2114405(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI2114405T1 publication Critical patent/SI2114405T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
SI200731644T 2006-12-28 2007-12-18 Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona SI2114405T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28
PCT/EP2007/064104 WO2008080821A1 (en) 2006-12-28 2007-12-18 Crystalline forms glyt1
EP07857734.3A EP2114405B1 (en) 2006-12-28 2007-12-18 methylparaben cocrystal form "A" of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2- ((S) -2,2,2-trifluoro- 1 -methyl-ethoxy) -phenyl] -methanone

Publications (1)

Publication Number Publication Date
SI2114405T1 true SI2114405T1 (sl) 2015-06-30

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731644T SI2114405T1 (sl) 2006-12-28 2007-12-18 Kokristalna oblika "a" metilparabena (4-(3-fluoro-5-trifluorometil-piridin-2-il)-piperazin-1-il)-(5-metan- sulfonil-2-((s)-2,2,2-trifluoro-1-metil-etoksi)-fenil)-metanona

Country Status (33)

Country Link
US (5) US20080214561A1 (OSRAM)
EP (1) EP2114405B1 (OSRAM)
JP (1) JP4799666B2 (OSRAM)
KR (1) KR101130146B1 (OSRAM)
CN (1) CN101573114A (OSRAM)
AR (1) AR064545A1 (OSRAM)
AU (1) AU2007341356B2 (OSRAM)
BR (1) BRPI0720829B8 (OSRAM)
CA (1) CA2673667A1 (OSRAM)
CL (1) CL2007003830A1 (OSRAM)
CO (1) CO6190613A2 (OSRAM)
CR (1) CR10846A (OSRAM)
CY (1) CY1116350T1 (OSRAM)
DK (1) DK2114405T3 (OSRAM)
EC (1) ECSP099471A (OSRAM)
ES (1) ES2535040T3 (OSRAM)
HR (1) HRP20150573T1 (OSRAM)
HU (1) HUE025032T2 (OSRAM)
MA (1) MA31029B1 (OSRAM)
MX (1) MX2009006859A (OSRAM)
MY (1) MY188367A (OSRAM)
NO (1) NO342150B1 (OSRAM)
NZ (1) NZ577502A (OSRAM)
PE (1) PE20081556A1 (OSRAM)
PL (1) PL2114405T3 (OSRAM)
PT (1) PT2114405E (OSRAM)
RS (1) RS53910B1 (OSRAM)
RU (1) RU2463295C2 (OSRAM)
SI (1) SI2114405T1 (OSRAM)
TW (1) TWI388552B (OSRAM)
UA (1) UA100232C2 (OSRAM)
WO (1) WO2008080821A1 (OSRAM)
ZA (1) ZA200904423B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ577502A (en) 2006-12-28 2012-02-24 Hoffmann La Roche Crystalline forms glyt1
JP6074142B2 (ja) 2009-02-26 2017-02-01 タール ファーマシューティカルズ，インコーポレイテッド 医薬化合物の結晶化
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
BR112014028872A2 (pt) * 2012-05-25 2017-06-27 Basf Se forma b cristalina, processo para a produção das formas b e ab, mistura da forma b cristalina, agente de proteção, uso da forma b cristalina e método para o combate do crescimento indesejado dos vegetais
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
EP4087570A4 (en) 2020-01-09 2024-04-03 Disc Medicine, Inc. METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS
JP7096958B2 (ja) * 2020-07-13 2022-07-06 日本碍子株式会社 精製方法
EP4337199A4 (en) * 2021-05-14 2025-03-19 Disc Medicine, Inc. Methods for treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibition agents
US20240390362A1 (en) * 2021-05-27 2024-11-28 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
UA85194C2 (ru) * 2003-08-11 2009-01-12 Ф.Хоффманн-Ля Рош Аг Пиперазины с or-замещенной фенильной группой и их применение как ингибиторов glyt 1
NZ577502A (en) 2006-12-28 2012-02-24 Hoffmann La Roche Crystalline forms glyt1

Also Published As

Publication number Publication date
JP4799666B2 (ja) 2011-10-26
MA31029B1 (fr) 2009-12-01
HRP20150573T1 (xx) 2015-07-03
WO2008080821A1 (en) 2008-07-10
RU2009124113A (ru) 2011-02-10
EP2114405B1 (en) 2015-03-11
KR20090094166A (ko) 2009-09-03
HUE025032T2 (en) 2016-02-29
RU2463295C2 (ru) 2012-10-10
UA100232C2 (uk) 2012-12-10
US20120309969A1 (en) 2012-12-06
DK2114405T3 (en) 2015-04-07
US20110295007A1 (en) 2011-12-01
NZ577502A (en) 2012-02-24
CY1116350T1 (el) 2017-03-15
MY188367A (en) 2021-12-06
CO6190613A2 (es) 2010-08-19
KR101130146B1 (ko) 2012-03-28
CL2007003830A1 (es) 2008-07-11
ES2535040T3 (es) 2015-05-04
US20080214561A1 (en) 2008-09-04
RS53910B1 (sr) 2015-08-31
NO20092358L (no) 2009-06-22
US20100311971A1 (en) 2010-12-09
BRPI0720829A2 (pt) 2014-02-25
PL2114405T3 (pl) 2015-08-31
TW200833677A (en) 2008-08-16
TWI388552B (zh) 2013-03-11
CR10846A (es) 2009-08-12
CA2673667A1 (en) 2008-07-10
AU2007341356B2 (en) 2013-08-29
EP2114405A1 (en) 2009-11-11
BRPI0720829B8 (pt) 2021-05-25
BRPI0720829B1 (pt) 2020-04-07
JP2010514725A (ja) 2010-05-06
AR064545A1 (es) 2009-04-08
ECSP099471A (es) 2009-07-31
US20130197225A1 (en) 2013-08-01
PE20081556A1 (es) 2008-11-28
CN101573114A (zh) 2009-11-04
US8039473B2 (en) 2011-10-18
MX2009006859A (es) 2009-07-03
ZA200904423B (en) 2010-05-26
PT2114405E (pt) 2015-06-02
NO342150B1 (no) 2018-04-03
AU2007341356A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
PL2114405T3 (pl) Mieszany kryształ postaci „A” [4-(3-fluoro-5-trifluorometylopirydyn-2- ylo)piperazyn-1-ylo]-[5-metanosulfonylo-2-((S)-2,2,2-trifluoro-1-metyloetoksy)fenylo]metanonu z metyloparabenem
IL238068A0 (en) New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
CY2020030I1 (el) Στερεες μορφες 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλο)-κυκλοπροπανοκαρβοξαμιλο)-3-μεθυλοπυριδιν-3-υλο)-βενζοϊκου οξεος
BRPI0716880A2 (pt) Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
EP1854318A4 (en) DYNAMIC IDENTITY ASSOCIATION IN A WIRELESS NETWORK
SI1919865T1 (sl) 1-heterociklilsulfonil, 2-aminometil, 5-(hetero-) arilno substituirani 1-H-pirolni derivati kot inhibitorji izločanja kisline
HRP20120173T1 (en) 1- ¦[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
EP1954683A4 (en) 2- (PHENYL OR HETEROCYCLYL) -1H-PHENANTHRO (9,10-D) IMIDAZOLE AS MPGES-1 INHIBITORS
PL2200985T3 (pl) 1,3-Dipodstawione-4-(arylo-X-fenylo)-1H-pirydyn-2-ony
CL2007003459A1 (es) Proceso de preparacion de compuestos derivados de pirimidina; y compuesto intermediario (s)-trans-etil 3-etoxi-7-(4-(4-fluorofenil)-6-isopropil-2-(n-metilmetilsulfonamido)pirimidin-5-il)-5-hidroxihep-2,6-dienoato.
SG173735A1 (en) Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
EP1962945A4 (en) EVALUATION OF ELECTRODE CLUTCH FOR TISSUE ABLATION
WO2006067103A3 (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
IL227951A0 (en) Crystalline and amorphous forms of -5-amino-1-[2,6-dichloro-4-(trifluoromethyl)-4-[(trifluoromethyl)sulfinyl]-1-h-carbonitrile
WO2005105096A3 (en) Fused heterocyclic compounds
WO2007057225A3 (en) Process for making montelukast and intermediates therefor
ZA200801813B (en) Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-(1,8)naphthyridin-2-one
WO2008108309A1 (ja) 縮環ピリジン誘導体
WO2007039117A3 (en) A process for the preparation of sartan derivatives and intermediates useful in such process
MX2009003106A (es) Nueva modificacion cristalina de 4-(n-metil-2-cloro-5-piridilmetil amino)-2,5-dihidrofuran-2-ona.
AU2016202490A1 (en) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
WO2007016139A3 (en) Crystalline non-solvated methanesulfonic acid salt of 1-(4-(2-piperidinylethoxy)phenoxy)-2-(3-hydroxyphenyl)-6-hydroxynaphthalene
WO2007057703A3 (en) Intermediate compounds for the preparation of statins
AU2006317419B2 (en) 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
AU2007905335A0 (en) A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes